WuXi PharmaTech

Latest Headlines

Latest Headlines

China's iKang seeks to delist from U.S. in latest healthcare exit

China's iKang Healthcare wants to go private in a management-led $1.1 billion offer that would see it delist from the U.S., making it among a handful of healthcare-related companies from the Middle Kingdom to pursue that strategy this year.

WuXi inks lab testing pact with Chinese Lee's Pharm

Chinese small-cap Lee's Pharm has signed CRO WuXi PharmaTech as its exclusive lab testing service to bolster the company's R&D program.

WuXi watches profits slip on its way to going private

Chinese CRO WuXi Pharma posted more soaring revenue in the second quarter, but some costly investments and currency issues drove down the company's profits as it prepares to go private.

Going private for WuXi PharmaTech opens dealmaking options

The word that China's top CRO WuXi PharmaTech would delist from the U.S. in a management-led $3.3 billion buyout opens up more paths to deal-making that may not reach the public as quickly.

CRO giant WuXi is going private in a $3.3B deal

WuXi PharmaTech, China's largest CRO, agreed to a $3.3 billion buyout deal that would take it off of Wall Street and into the hands of some private investors.

WuXi advances edible bar codes, a novel approach to counter-counterfeiting

Chinese CRO WuXi PharmaTech, alongside partner TruTag Technologies, is developing tiny, edible bar codes designed to prevent drug counterfeiting, and the technology cleared its first hurdle.

WuXi bets $50M on a new venture fund and eyes $200M more

Chinese CRO giant WuXi PharmaTech is looking to expand its investment portfolio, planning to debut a $250 million new fund that will back startups in the U.S. and China.

WuXi Healthcare Ventures plucks $50M from WuXi PharmaTech as anchor for second fund

U.S. and China focused WuXi Healthcare Ventures Fund picked up $50 million from affiliated WuXi PharmaTech, the sprawling China-based biopharma CRO, according to documents filed with the U.S. Securities and Exchange Commission. 

WuXi selling chunk of SynTheAll to raise $80M for plant expansion

WuXi PharmaTech has been in expansion mode for its manufacturing, which of course, comes with financing pressures. To raise some cash for the expansion of its small-molecule manufacturing subsidiary, SynTheAll Pharmaceutical, WuXi intends to sell off 6% of the business in anticipation of raising $80 million.

UPDATED: WuXi files a 406 extension with U.S. SEC. What's the secret?

WuXi PharmaTech sought and has been approved for an extension under U.S. Securities and Exchange Commission Rule 406 to keep confidential treatment of information excluded from Form F-1 filed on July 24, 2007, as amended, according to an order filed June 17.